Clinical Trials Browser

OTHER × tislelizumab × Gynecologic × Clear all

NCT05044871 2025-06-08

BRIGHT

Phase 2 Completed

Ovarian Neoplasms

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Phase EARLY_PHASE1 Terminated

GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Phase NA Not yet recruiting

Neoplasms, Endometrial Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT06063018 2023-10-02

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Phase 2 Recruiting

Cervical Cancer Recurrent

NCT06039891 2023-09-15

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Phase 2 Not yet recruiting

Uterine Cervical Neoplasms

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05614453 2023-06-29

ITTACC

Phase 2 Withdrawn

Uterine Cervical Neoplasms

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT05310383 2022-04-11

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Phase 2 Unknown

Uterine Cervical Neoplasms

NCT04815408 2021-03-25

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms